JP2021531831A5 - - Google Patents

Info

Publication number
JP2021531831A5
JP2021531831A5 JP2021528324A JP2021528324A JP2021531831A5 JP 2021531831 A5 JP2021531831 A5 JP 2021531831A5 JP 2021528324 A JP2021528324 A JP 2021528324A JP 2021528324 A JP2021528324 A JP 2021528324A JP 2021531831 A5 JP2021531831 A5 JP 2021531831A5
Authority
JP
Japan
Prior art keywords
individual
gene expression
cutaneous melanoma
expression signature
primary cutaneous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021528324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531831A (ja
JP7633159B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2019/050487 external-priority patent/WO2020022895A2/en
Publication of JP2021531831A publication Critical patent/JP2021531831A/ja
Publication of JP2021531831A5 publication Critical patent/JP2021531831A5/ja
Application granted granted Critical
Publication of JP7633159B2 publication Critical patent/JP7633159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021528324A 2018-07-25 2019-07-25 メラノーマの転移及び患者の予後を予測するための遺伝子シグネチャー Active JP7633159B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862703221P 2018-07-25 2018-07-25
US62/703,221 2018-07-25
US201862750294P 2018-10-25 2018-10-25
US62/750,294 2018-10-25
US201862778777P 2018-12-12 2018-12-12
US62/778,777 2018-12-12
PCT/NL2019/050487 WO2020022895A2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Publications (3)

Publication Number Publication Date
JP2021531831A JP2021531831A (ja) 2021-11-25
JP2021531831A5 true JP2021531831A5 (enExample) 2022-07-28
JP7633159B2 JP7633159B2 (ja) 2025-02-19

Family

ID=68242821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021528324A Active JP7633159B2 (ja) 2018-07-25 2019-07-25 メラノーマの転移及び患者の予後を予測するための遺伝子シグネチャー

Country Status (11)

Country Link
US (2) US12473599B2 (enExample)
EP (1) EP3827101B1 (enExample)
JP (1) JP7633159B2 (enExample)
KR (1) KR20210044233A (enExample)
CN (1) CN113039289B (enExample)
AU (1) AU2019310636B2 (enExample)
CA (1) CA3107401A1 (enExample)
DK (1) DK3827101T3 (enExample)
ES (1) ES2966015T3 (enExample)
IL (1) IL280377A (enExample)
WO (1) WO2020022895A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102751357B1 (ko) * 2021-07-16 2025-01-06 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군
CA3240376A1 (en) * 2021-12-08 2023-06-15 Alexander MEVES Assessing and treating melanoma
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060136145A1 (en) 2004-12-20 2006-06-22 Kuo-Jang Kao Universal reference standard for normalization of microarray gene expression profiling data
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
PT2062049E (pt) 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
EP2152911A4 (en) 2007-05-04 2010-05-19 Dermtech Int DIAGNOSIS OF MELANOMA BY NUCLEIC ACID ANALYSIS
EP2228457A1 (en) 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
CA2716357A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
RU2011142806A (ru) 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2619321B1 (en) 2010-09-20 2018-08-01 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2014077915A1 (en) 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
AU2017261688B2 (en) 2016-05-10 2022-09-29 Mayo Foundation For Medical Education And Research Methods and materials for staging and treating skin cancer

Similar Documents

Publication Publication Date Title
JP2021531831A5 (enExample)
US11776664B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP7241352B2 (ja) 肺扁平上皮癌のサブタイピングのための方法
CN111402949A (zh) 一种肝细胞肝癌患者诊断、预后和复发统一模型的构建方法
US20260071281A1 (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
US20210074431A1 (en) Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
AU2020204060A1 (en) Genes and gene signatures for diagnosis and treatment of melanoma
Noro et al. A two-gene prognostic classifier for early-stage lung squamous cell carcinoma in multiple large-scale and geographically diverse cohorts
CN106282321A (zh) 由组织snoRNA组成的肝癌复发风险预测标志物及试剂盒
Lima et al. FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer
CN106811525B (zh) 一种预测ⅲ期胃癌患者术后早期复发的试剂盒和系统
CN110055327A (zh) 用于预测癌症免疫治疗效果的内皮细胞标记物与试剂盒
Maliniemi et al. Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression-and autoimmunity-associated genes
AU2022200004B2 (en) Genes and gene signatures for diagnosis and treatment of melanoma
Sippl et al. The influence of distinct regulatory miRNAs of the p15/p16/RB1/E2F pathway on the clinical progression of glioblastoma multiforme
CN112048555A (zh) 胶质瘤患者生存预测的预后分类系统
Klopstock et al. HCV tumor promoting effect is dependent on host genetic background
Xie et al. Validation of the reference genes for the gene expression studies in different cell lines of pig
US20150376714A1 (en) Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
JP2020524524A5 (enExample)
Kumar et al. Evaluation of fibroblast growth factor receptor 3 (FGFR3) and tumor protein P53 (TP53) as independent prognostic biomarkers in high-grade non-muscle invasive bladder cancer
WO2022006596A1 (en) A single patient classifier for t1 high grade bladder cancer
CN107663540A (zh) 一种与癌症相关的分子标志物及其检测方法
CN107574249B (zh) 一种预测中国人群乳腺癌复发的基因表达谱检测试剂盒
Baghel et al. Elevated expression of maspin mRNA as a predictor of survival in stage II and III gallbladder cancer cases